A Phase 4 interventional study of Antibiotics in UTI, sponsored by Megan Bradley. Completed at 1 site in United States. Open to female participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-08-27.
Sponsored by Megan Bradley · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate the feasibility of recruiting eligible subjects into a randomized trial of a culture-directed versus empiric antibiotic strategy for patient-reported urinary tract infection symptoms in older women and the adherence to study procedures.
To evaluate A) the feasibility of recruiting eligible subjects into a randomized trial of a culture-directed versus empiric antibiotic strategy for patient-reported urinary tract infection (UTI) symptoms in older women and B) the adherence to study procedures. We will recruit and enroll women with a history of recurrent UTI (rUTI) from the Women's Center for Bladder and Pelvic Health and the University of Pittsburgh's Clinical and Translational Science Institute (CTSI) Pitt+Me® Research Registry. Once enrolled and randomized, women will be followed for a total of 28 days to document both clinical resolution at day 7 from symptom onset and adverse events. H1) Enrolling a total of 70 subjects in \<1 year (at least 10% of eligible patients) will demonstrate feasibility of recruitment and H2) Documenting at least 70% patient compliance with study procedures will confirm patient adherence to study protocol. Exploratory Aim: To explore the safety of a culture-directed UTI treatment strategy and preliminary secondary outcomes of assigned treatments. H1) There will be an overall low number of adverse events and H2) Preliminary outcome data will help power future trial.
Megan Bradley is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient reported UTI defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be directed to refrain from taking antibiotics until results of urine culture are reported, which is expected within 48-72h.
Drug: Antibiotics
Antibiotic Protocol. For participants in the empiric Rx arm, we will choose an antibiotic with consideration of patient reported allergies, current medications and current Infectious Disease Society of American (IDSA) guidelines. If there is a contraindication to the first antibiotic on the list they will progress to the next option until a suitable selection is achieved.
Drug: Antibiotics
Participants will be provided either nitrofurantoin 100 mg oral twice a day for 5 days, trimethoprim/sulfamethoxazole 875/125 oral twice a day for 3 days, fosfomycin 3g once oral, ciprofloxacin 250 mg oral twice a day for 5 days or cephalexin 500 mg oral twice a day for 5 days
Eligible Subjects That Were Enrolled in the Study
Number and proportion of eligible subjects that were enrolled in the study
Time frame: Through study completion, an average of 17.5 months
Number of Persons That Were Screened for Participation
Overall number of persons that were screened for participation
Time frame: Through study completion, an average of 17.5 months
Proportion of Persons Screened Who Met Inclusion/Exclusion Criteria
Number of person screened who met include/exclusion criteria divided by number participants screened
Time frame: 30 days
Proportion of Persons Screened Who Declined Participation or Were Ineligible
Number of person screened who declined or were ineligible divided by number participants screened
Time frame: 30 days
Proportion of Participants Enrolled Who Completed the Study
Number of persons enrolled who completed the study (at least one follow-up questionnaire and completed the day 28 questionnaire) divided by number participants enrolled
Time frame: 30 days
Monthly Enrollment Rate
number of participants that were enrolled each month
Time frame: Through study completion, an average of 17.5 months
Proportion of Enrolled Participants That Completed All Study Procedures
Number of persons enrolled who completed all study procedures (completed all 4 follow-up questionnaires) divided by number participants enrolled
Time frame: 30 days
Proportion of Enrolled Participants That Took Alternative Agents for Management of Symptoms
Number of persons enrolled who took alternative agents for management of symptoms divided by number participants enrolled
Time frame: 30 days
Proportion of Participants in the Culture-directed Arm That Acquired Off-protocol Antibiotics for Their Symptoms
Number of participants in the culture-directed arm that acquired off-protocol antibiotics for their symptoms divided by the number of participants in the culture-directed arm
Time frame: 30 days
Proportion of Enrolled Participants That Completed Electronic Surveys
Number of persons enrolled who completed all electronic surveys divided by number participants enrolled
Time frame: 30 days
Clinical Success at 14 Days
Score of \<1 on question 1 (urinary burning),3 (urinary urgency) and 5 (urinary frequency) on Urinary Tract Infection Symptom Assessment at day 14. A lower scale correlates with better symptoms with 0 being no symptoms and 1 being "little" symptoms.
Time frame: 14 days
| Milestone | Culture-directed Antibiotic | Empiric Antibiotic |
|---|---|---|
| Started | 35 | 35 |
| Completed | 31 | 31 |
| Not completed | 4 | 4 |
Number and proportion of eligible subjects that were enrolled in the study
| Participants | Overall Number and Proportion of Eligible Subjects That Were Enrolled in the Study |
|---|---|
| Eligible Subjects That Were Enrolled in the Study | 70 |
Overall number of persons that were screened for participation
| Participants | Number of Subjects That Were Screened for Participation |
|---|---|
| Number of Persons That Were Screened for Participation | 131 |
Number of person screened who met include/exclusion criteria divided by number participants screened
| Participants | Number and Proportion of Subjects Screened Who Met Inclusion/Exclusion Criteria |
|---|---|
| Proportion of Persons Screened Who Met Inclusion/Exclusion Criteria | 103 |
Number of person screened who declined or were ineligible divided by number participants screened
| Participants | Proportion of Persons Screened Who Declined Participation or Were Ineligible |
|---|---|
| Proportion of Persons Screened Who Declined Participation or Were Ineligible | 43 |
Number of persons enrolled who completed the study (at least one follow-up questionnaire and completed the day 28 questionnaire) divided by number participants enrolled
| Participants | Culture-directed Antibiotic | Empiric Antibiotic |
|---|---|---|
| Proportion of Participants Enrolled Who Completed the Study | 30 | 31 |
number of participants that were enrolled each month
| participants enrolled per month | Monthly Enrollment Rate |
|---|---|
| Monthly Enrollment Rate | 4 (2 to 5) |
Number of persons enrolled who completed all study procedures (completed all 4 follow-up questionnaires) divided by number participants enrolled
| Participants | Culture-directed Antibiotic | Empiric Antibiotics |
|---|---|---|
| Proportion of Enrolled Participants That Completed All Study Procedures | 30 | 31 |
Number of persons enrolled who took alternative agents for management of symptoms divided by number participants enrolled
| Participants | Culture-directed Antibiotic | Empiric Antibiotic |
|---|---|---|
| Proportion of Enrolled Participants That Took Alternative Agents for Management of Symptoms | 16 | 10 |
Number of participants in the culture-directed arm that acquired off-protocol antibiotics for their symptoms divided by the number of participants in the culture-directed arm
| Participants | Culture-directed Arm |
|---|---|
| Proportion of Participants in the Culture-directed Arm That Acquired Off-protocol Antibiotics for Their Symptoms | 1 |
Number of persons enrolled who completed all electronic surveys divided by number participants enrolled
| Participants | Culture-directed Antibiotic | Empiric Antibiotics |
|---|---|---|
| Proportion of Enrolled Participants That Completed Electronic Surveys | 30 | 31 |
Score of \<1 on question 1 (urinary burning),3 (urinary urgency) and 5 (urinary frequency) on Urinary Tract Infection Symptom Assessment at day 14. A lower scale correlates with better symptoms with 0 being no symptoms and 1 being "little" symptoms.
| Participants | Culture-directed Antibiotic | Empiric Antibiotic |
|---|---|---|
| Clinical Success at 14 Days | 19 | 12 |
Collected over 28 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Culture-directed Antibiotic | 0/35 (0%) | 0/35 (0%) | 5/35 (14.3%) |
| Empiric Antibiotic | 0/35 (0%) | 0/35 (0%) | 0/35 (0%) |
| Event | Culture-directed Antibiotic | Empiric Antibiotic |
|---|---|---|
| DiarrheaGastrointestinal disorders | 5/35 | 0/35 |
| Nausea/Vomiting SymptomsGastrointestinal disorders | 3/35 | 0/35 |
| RashSkin and subcutaneous tissue disorders | 0/35 | 0/35 |
| Age, Continuous(years) | Culture-directed Antibiotic | Empiric Antibiotic | Total |
|---|---|---|---|
| Mean | 74.1 ± 7.1 | 75.7 ± 6.8 | 74.9 ± 6.9 |
| Sex: Female, Male(Participants) | Culture-directed Antibiotic | Empiric Antibiotic | Total |
|---|---|---|---|
| Female | 35 | 35 | 70 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Culture-directed Antibiotic | Empiric Antibiotic | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 35 | 34 | 69 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Culture-directed Antibiotic | Empiric Antibiotic | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 35 | 34 | 69 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Number of Participants with Diabetes Mellitus(Participants) | Culture-directed Antibiotic | Empiric Antibiotic | Total |
|---|---|---|---|
| Count of participants | 5 | 6 | 11 |
| BMI(kg/m^2) | Culture-directed Antibiotic | Empiric Antibiotic | Total |
|---|---|---|---|
| Mean | 30.5 ± 7.6 | 28.5 ± 6.1 | 29.5 ± 6.9 |
| Pelvic Floor Distress Inventory-20(units on a scale) | Culture-directed Antibiotic | Empiric Antibiotic | Total |
|---|---|---|---|
| Mean | 137.9 ± 59.9 | 146.0 ± 68.0 | 142.0 ± 63.7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Will review each request individually and work with University of Pittsburgh Research Agreements to share.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: 1 year after completion
Access criteria: unknown at this time
Ran from Feb 2023 to primary completion in Aug 2024, 17 months.
Results were first posted in Aug 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Megan Bradley